Low-Frequency
Chimeric Antigen Receptor T-cell (CAR T)
Clonal Hematopoiesis (CH)
Diffuse Large B-cell Lymphoma (DLBCL)
Next-Generation Sequencing (NGS)
Protein Phosphatase Mg/Mn-dependent 1D (PPM1D)
Wild-type p53-induced phosphatase 1 (Wip1)
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
13 Dec 2023
13 Dec 2023
Historique:
received:
23
10
2023
revised:
20
11
2023
accepted:
08
12
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
epublish
Résumé
Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the
Identifiants
pubmed: 38132396
pii: curroncol30120762
doi: 10.3390/curroncol30120762
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM